Rapid advances in biomarker research improve outcomes for people with cancer. National Comprehensive Cancer Network Patient Advocacy Summit looks at policy and practice solutions to increase equitable access for all.
NCCN announces updates on the NCCN Distress Thermometer and Problem List -- a free resource to help providers worldwide identify and address the unpleasant experiences that may make it harder to cope with having cancer, its symptoms, or treatment.
National Comprehensive Cancer Network shares new guide on effective tools for preventing and early detection of colorectal cancer and reducing cancer death; providing patients and caregivers free access to the latest expert recommendations at NCCN.org/patientguidelines.
New research in JNCCN—Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial medication called all-trans retinoic acid (ATRA), initiated early in the treatment of acute promyelocytic leukemia (APL)—a form of acute myeloid leukemia (AML).
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
International collaboration involving NCCN and Polish oncology officials publishes first of several evidence-based expert consensus guidelines with latest cancer treatment recommendations, adapted for regional needs, beginning with cervical cancer.
New research in JNCCN based on patient surveys before and during the COVID-19 pandemic, found higher percentage preferred telemedicine and that general patient satisfaction scores were equally high for both video conferencing and office visits.
New NCCN Guidelines for Patients: Basal Cell Skin Cancer empowers patients and caregivers with knowledge about this widespread, preventable, and easily-cured cancer plus the rare subset that requires more aggressive treatment.
The NCCN Virtual Congress: Hematologic Malignancies (#NCCNhem21) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online Thursday, October 14, 2021 – Saturday, October 16, 2021. The NCCN Virtual Nursing Forum will be held October 8, 2021.
NCCN announces the publication of new NCCN Guidelines for Patients®: Small Cell Lung Cancer (SCLC), which is a neuroendocrine tumor type of lung cancer that is linked to smoking and tends to be aggressive. This guide is free to view or download at NCCN.org/patientguidelines and is funded by NCCN Foundation®.
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
Participants at National Comprehensive Cancer Network (NCCN) Virtual Policy Summit discuss the potential for imaging and other emerging technologies to improve cancer care while not increasing disparities.
National Comprehensive Cancer Network (NCCN) Vaccination Advisory Committee updates recommendations for vaccinating people with cancer against COVID-19 based on regulatory changes and emerging data regarding third doses (aka boosters).
New study in JNCCN finds that among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, in first population-based cohort study on cancer-specific death after a NET diagnosis.
National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee calls for healthcare workforce vaccine requirements to assure healthcare community is doing all it can to prevent exposure to COVID-19.
New research in the July 2021 issue of JNCCN indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States. Researchers found 85.4% of centers offered mental health services but only 45.5% had chemical dependency services.
The NCCN Oncology Research Program (ORP) announces projects that have been selected for funding to evaluate neratinib in various tumor types, supported by a grant from Puma Biotechnology, Inc.
NCCN, an alliance of 31 leading cancer centers, has again qualified as a provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS), the nation’s largest health payer.
New research in the June 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network assesses the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers.
New and updated patient and caregiver resources from National Comprehensive Cancer Network (NCCN) offer jargon-free, state-of-the-art information on diagnosis, treatment, and surveillance for anal, colon, and rectal cancers.
NCCN Policy Summit examines the impact of the past year on oncology policy in the U.S., such as resuming recommended screening and clinical trials, applying health innovations from the COVID-19 pandemic to cancer treatment, and addressing systemic inequalities that lead to disparities in outcomes.
National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.
Free resource from the National Comprehensive Cancer Network helps employers select health plans and provide services to improve employee outcomes and minimize disruptions from cancer diagnoses—now available at NCCN.org/employertoolkit
NCCN annual award recognizes Dr. Mary Daly for her pioneering role in the field of genetics and family history in assessing cancer risk, particularly for breast, ovarian, and pancreatic cancers.
New resource from NCCN helps cancer patients and caregivers recognize and understand blood cell production deficiencies, to better participate in their care planning; available for free at NCCN.org/patientguidelines.
National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg).
International study finds 4% of patients with metastatic renal cell carcinoma developed asymptomatic brain metastases, which correlated to poorer outcomes.
New recommendations to advance racial equity, mitigate the impacts of COVID-19 on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led the conversation at the NCCN 2021 Virtual Annual Conference March 18-20 with more than 1,300 attendees from 40 countries.
NCCN announced that it has elected University of California (UC) Davis Comprehensive Cancer Center as its newest Member Institution joining 30 other leading academic cancer centers to improve and facilitate quality, effective, efficient, and accessible cancer care so patients can live better lives.
National Comprehensive Cancer Network Oncology Research Program selects ten projects to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology.
Results of new study in JNCCN from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
NCCN announces the publication of new NCCN Guidelines® for Histiocytic Neoplasms, rare disorders characterized by a buildup of white blood cells leading to tissue damage. The three most-common forms are Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman disease.
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN) and the National Minority Quality Forum (NMQF) presented new ideas for overcoming inequality in oncology. The recommendations address how medical systems often disproportionately fail minority patients.
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
The National Comprehensive Cancer Network® (NCCN®) today announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation®. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society.
For World Cancer Day 2021, National Comprehensive Cancer Network (NCCN) employees took part in a 21-day challenge to get personal about cancer care, by sharing a look at how different staff members’ lives have been directly impacted by cancer.
The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) are teaming up with leading cancer organizations across the country to endorse prioritizing the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic. The coalition of 76 organizations is releasing an open letter about the threat cancer still poses to people’s health and a reminder that acting as soon as is safely possible can lead to much better outcomes in the future.
The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.
The National Comprehensive Cancer Network (NCCN) announces Crystal S. Denlinger, MD, FACP, as incoming Senior Vice President, Chief Scientific Officer. Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP).
New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers.
NCCN announces the publication of new, free informational resources on health and wellness for cancer survivors. Two new NCCN Guidelines for Patients® focus on healthy living and managing late and long-term side effects, and include appropriate ongoing screening for recurrence.
National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.
Virtual NCCN Policy Summit from the National Comprehensive Cancer Network explores how health policymakers can respond to the needs and wishes of people with cancer across all ages.
The NCCN Oncology Research Program (ORP) today announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib, a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of HR+ and HER2- breast cancer.
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
The National Comprehensive Cancer Network® (NCCN®) today announced the addition of Beth Gaffney, MBA, as the new Vice President of U.S. and Global Business Development, overseeing licensing and other collaborations.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right